The Pharma Data

OCTOBER 14, 2020

The highly potent and selective payload series represents a powerful new class within ADC development with novel protein alkylating cytotoxicity. Under the terms of the non-exclusive agreement FASMAC acquires the right to use CRISPR/Cas9 technology and commercialize tools and reagents associated with it.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing In-Vivo 52

XTalks

MARCH 11, 2025

Rapid assays that can deliver same-day results are highly attractive to pharma companies, as they eliminate lengthy sample queues often seen with centralized or outsourced testing. The result was a prepackaged, off-the-shelf reagent kit that provided reliable quantification for a wide variety of influenza mRNA vaccine constructs.

Vaccination 64

Vaccination Vaccine Development Manufacturing 64

XTalks

JANUARY 6, 2025

RNA-Based Therapeutics RNA molecules have emerged as promising therapeutic agents due to their ability to precisely target undruggable proteins or molecules, often with minimal side effects. The global next-generation biomanufacturing market is projected to grow at a CAGR of 14.85 percent from 2021 to 2031, reaching an estimated value of $85.2

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111